Jabil has acquired contract development and manufacturing organisation (CDMO) Pharmaceutics International (Pii) to offer support for drug development customers.

The acquisition of Pii enhances Jabil's current pharmaceutical offerings and allows for assistance to clients throughout clinical trials and product commercialisation at scale.

The move strengthens Jabil's offerings, particularly in the development and commercial production of on-body pumps, pen injectors, auto-injectors and inhalers.

Pii's addition to Jabil's portfolio brings scientific expertise and a comprehensive range of pharmaceutical development and manufacturing services.

It includes lyophilisation, aseptic filling and manufacturing of oral solid doses, enhancing Jabil's ability to meet the clinical and commercial drug manufacturing needs of healthcare customers.

Jabil pharmaceutical solutions vice-president James O’Gorman stated: “Jabil is very pleased to announce this acquisition. With our shared commitment to creating the best solutions possible for patients around the world, we believe the addition of Pii’s capabilities, supported by 300 team members, is a perfect fit for Jabil and our customers.”

On integration into Jabil, Pii will benefit from an expanded global infrastructure, automation and supply chain efficiencies.

Pii CEO and president John Fowler stated: “This acquisition marks an exciting new chapter for Pii. We look forward to leveraging Jabil’s extensive expertise to accelerate our mission of delivering best-in-class drug development and manufacturing solutions to our customers and ultimately the patients we serve.”

Pii has developed 40 soft gel products, securing approvals for multiple commercial products, and currently has two new drug application products in the pipeline.

Founded in 1994, it has expanded its operations to more than 360,000ft² across four sites located on one campus in Hunt Valley, Maryland, US.